Fig. 1From: Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case reportImmunohistochemistry (IHC) of a recurrent tumor (China Medical University Hospital). a Representative histological features (H&E, 100×). b Representative histological features (H&E, 400×). c Corresponding images of PD-L1 staining (IHC 22C3 pharmDx Assay, Agilent/Dako, 400×). d Corresponding images of PD-L1 staining (IHC 28–8 pharmDx Assay, Agilent/Dako, 400×)Back to article page